Chiron Minority Shareholder Will Oppose Novartis Takeover
This article was originally published in The Pink Sheet Daily
Executive Summary
Shareholder ValueAct Capital owns 5% of Chiron's shares and 9% of non-Novartis-owned shares.
You may also be interested in...
Novartis Cements Chiron Buy With Increased Bid
Chiron shareholders have agreed to vote in favor of the takeover at $48 per share, up from $45 per share deal Chiron accepted in October.
Novartis Cements Chiron Buy With Increased Bid
Chiron shareholders have agreed to vote in favor of the takeover at $48 per share, up from $45 per share deal Chiron accepted in October.
Chiron’s Adjuvant Could Quadruple Flu Vaccine Capacity, CEO Pien Says
The firm will meet with FDA to determine the regulatory pathway for the MF59 adjuvant in 2006.